XML 29 R17.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Segment Reporting Disclosure Segment Reporting
The Company has one reportable segment. The Company’s chief operating decision maker is the Chief Executive Officer and President. The accounting policies of the single segment are the same as those described in the summary of significant accounting policies. The chief operating decision maker assesses performance for the single segment and decides how to allocate resources based on net loss that also is reported on the condensed and consolidated statements of operations and comprehensive income (loss) as consolidated net loss. The chief operating decision maker uses net loss to monitor budget versus actual results and to evaluate the overall cash burn of the business.

Three Months Ended September 30,Nine Months Ended September 30,
2025202420252024
(in thousands)
Revenue$529 $1,339 $13,032 $4,597 
Less:
Research and development employee expense, lab supplies and overhead3,194 6,166 9,927 20,174 
Imdusiran IM-PROVE I, II & III clinical trials expense1,073 5,031 4,862 14,430 
AB-101-001 Phase 1a/1b clinical trial expense1,134 2,931 4,771 8,927 
Other research and development programs expense377 145 675 1,696 
General and administrative expense3,044 4,537 12,204 17,396 
Restructuring expense98 3,625 12,636 3,625 
Other segment expense (1)
303 367 893 857 
Add:
Interest income952 1,746 3,191 5,120 
Segment net loss$(7,742)$(19,717)$(29,745)$(57,388)
Adjustments and reconciling items— — — — 
Consolidated net loss$(7,742)$(19,717)$(29,745)$(57,388)

(1) Other segment expense includes the change in the fair value of contingent consideration, non-cash interest expenses and foreign currency exchange gains and losses.